ZIMMER BIOMET HOLDINGS, INC. 8-K

What Happened

• Zimmer Biomet Holdings, Inc. announced on June 26, 2026 that it entered into two new unsecured revolving credit agreements with JPMorgan Chase Bank, N.A. as administrative agent: a Five-Year Revolving Credit Agreement ($1.5 billion) and a 364‑Day Revolving Credit Agreement ($1.25 billion).
• The new five‑year facility matures June 26, 2031 (with two one‑year extension options and an uncommitted incremental feature up to $750 million). The 364‑day facility matures June 25, 2027. Both facilities bear interest at adjusted Term SOFR (or an alternate base rate) plus a margin tied to Zimmer Biomet’s senior unsecured long‑term debt rating.

Key Details

• Effective date: June 26, 2026. Lender/agent: JPMorgan Chase Bank, N.A.
• Five‑Year Revolving Facility: $1.5 billion committed; incremental increase option up to $750 million; maturity June 26, 2031; facility fee and interest margin set by company credit rating.
• 364‑Day Revolving Facility: $1.25 billion; maturity June 25, 2027; similar pricing mechanics tied to credit rating.
• Both agreements include customary covenants and defaults for unsecured financings and require Zimmer Biomet to maintain a consolidated indebtedness / consolidated EBITDA ratio no greater than 4.5:1 (can rise to 5.0:1 for certain qualified acquisitions).
• The prior 2025 five‑year and 2025 364‑day credit agreements were terminated on June 26, 2026 with no outstanding principal; approximately $0.4 million of fees under the prior five‑year agreement were paid in full. Existing letters of credit under the prior facility were transferred to the new five‑year facility.

Why It Matters

• These new facilities establish committed liquidity of $2.75 billion and extend the company’s debt maturity profile (longer‑term facility to 2031), which supports general corporate needs and short‑term funding flexibility.
• Pricing and fees tied to Zimmer Biomet’s credit rating mean borrowing costs will move with the company’s credit profile; the leverage covenant (debt/EBITDA cap) is a notable limitation investors should watch when assessing potential additional debt or large acquisitions.
• Transitioning letters of credit to the new facility and terminating the prior agreements simplifies the company’s credit structure and confirms no outstanding principal under the old facilities as of the termination date.